Navigation Links
Cardiac Science Adds NextGen to Its Roster of Certified EMR System Partners

BOTHELL, Wash., March 31 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, announced today at the 2008 American College of Cardiology conference that it completed certification for its HeartCentrix(R) ECG informatics software with NextGen Healthcare Information Systems. NextGen is a leading developer and provider of computer-based practice management and electronic medical record (EMR) systems for medical group practices and healthcare systems.


Featuring the industry's most robust cardiology knowledgebase, the NextGen EMR system is used by more than 1,500 clients nationwide -- including many leading cardiology practices. These current clients, as well as future clients, will be readily able to take advantage of connectivity to the HeartCentrix(R) informatics software. In addition, the integration will be leveraged through the tens of thousands in Cardiac Science's installed base of customers.

Designed to integrate seamlessly EMR and other information systems, HeartCentrix solutions help streamline workflow in multiple health care environments. HeartCentrix -- which enables seamless data transfer from Burdick(R) and Quinton(R) electrocardiograph (ECG) devices, cardiac stress, and Holter monitoring devices to physician EMR software -- can be installed with a new NextGen EMR implementation, or just as easily into an existing NextGen account.

Tony Titus, Cardiac Science vice president of marketing, reported that HeartCentrix and NextGen recently began deployment for their first joint installation, a multi-site cardiology practice of more than 60 physicians. "Pairing HeartCentrix with NextGen connects diagnostic devices and EMR systems together for office-wide efficiencies, and a greater ROI on the EMR investment," he said.

"HeartCentrix is a great solution for our clients who rely on Burdick and Quinton diagnostic devices in particular," said Debra Dore, director of cardiology products for NextGen. "Bringing information from HeartCentrix into the NextGen EMR platform will enable a smoother office workflow, faster diagnosis and therapeutic decision-making and, ultimately, better patient care."

About NextGen

NextGen Healthcare Information Systems, Inc. a wholly owned subsidiary of Quality Systems, Inc. (Nasdaq: QSII), develops and markets computer-based practice management and electronic medical records systems for medical group practices and healthcare systems. For more information about NextGen, please visit and

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The Company sells a variety of related products and consumables, and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit

Forward Looking Statements

This press release contains forward-looking statements. These statements and their underlying assumptions involve a number of risks and uncertainties and are not guarantees of future performance. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward looking. Actual results may vary significantly from the results expressed or implied in such statements. Forward looking statements in this press release include those that infer or imply that the revenue and profits of Cardiac Science may increase as a result of the connectivity of its products with those of NextGen Healthcare Information Systems and other information systems, as well as other risks that are more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2007. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

Company Contact: Investor Contact: Media Contact:

Mike Matysik Jenifer Kirtland Christopher Gale

Cardiac Science Corporation EVC Group, Inc. EVC Group, Inc.

Sr. Vice President and CFO (415) 896-6820 (201) 646-5431

(425) 402-2009 (203) 570-4681 CSCX-G

SOURCE Cardiac Science Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Heart Failure Raises Risks After Non-Cardiac Surgeries
2. Medical Simulation Corporation to Present Comprehensive Cardiac Patient Scenario at the Society for Cardiovascular Angiography and Interventions (SCAI) and American College of Cardiology (ACC) Conference
3. SCAI Applauds CMS Decision to Continue Coverage of Cardiac CT Scans
4. Cardiovascular nursing: Striving for excellence in the care of cardiac patients
5. Vital Images Comments on CMS Decision to Allow Local Coverage for Cardiac CT Angiography
6. Researchers make case for standardized analysis of cardiac imaging
7. Cardiac Science to Present at the Seventh Annual Invest Northwest Conference
8. New Method Boosts Cardiac Arrest Survival
9. Cardiac Science Delivers Largest Order of Electrocardiograph Systems in Company History
10. Cardiac effects associated with breast cancer treatment appear lower with dose-dense chemotherapy
11. Moderate alcohol consumption in middle age can lower cardiac risk
Post Your Comments:
(Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... automated breast density assessment and enterprise analytics solutions, here at the 101st ... (South Hall booth #2377). Volpara’s quantitative breast imaging tools enable personalized measurements ...
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone will experience ... friend, or animal pass away, death lives among us. It is your perspective, however, ... a family of 11 children, author T Sky understands that she may see death ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case ... from three innovative value-based care arrangements: Essentia Health and UCare, MissionPoint Health ...
(Date:11/30/2015)... , ... November 30, 2015 , ... The successful filing ... pharmaceutical company. Because it is so important to this key industry segment, Regis Technologies ... your IND Filing” on December 4th at 11am EST. , Federal law does not ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Cumberland Pharmaceuticals (CPIX), today announced that A.J. Kazimi ... December 3, 2015. TIME: 3:15p.m. ET LINK: ... --> DATE: Thursday, December ... --> --> This will ... to ask the company questions in real-time - both in ...
(Date:11/30/2015)... Nov. 30, 2015 Varian Medical Systems (NYSE: VAR ... educational partnership with Apollo Hospitals Group, the largest hospital chain in ... help train radiation technologists in the country. The MoU was signed ... Knowledge, and Ashok Kakkar , Varian,s India ... India , Varian intends to deploy its Access ...
(Date:11/30/2015)... , November 30, 2015 PFE ... at up to 10 G protein-coupled receptor (GPCR) targets ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> Heptares Therapeutics ("Heptares"), ... and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; TSE ...
Breaking Medicine Technology: